Document Detail

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.
MedLine Citation:
PMID:  21183326     Owner:  NLM     Status:  Publisher    
BACKGROUND: Static and dynamic lung hyperinflation are associated with exercise impairment and poor outcomes in COPD patients. Aclidinium bromide is a novel, long-acting inhaled muscarinic antagonist currently in development for COPD treatment. METHODS: Patients with moderate to severe COPD (N = 181) were randomized to once-daily aclidinium 200 μg or placebo for 6 weeks. Constant work rate cycling exercises at 75% of peak work rate were performed at baseline, Day 1, Week 3, and Week 6. The primary efficacy measure was change in exercise endurance time (ET) from baseline to Week 6. Secondary outcomes included changes in trough forced expiratory volume in 1 s (FEV(1)), inspiratory capacity (IC), IC/total lung capacity (TLC), and functional residual capacity (FRC) from baseline to Day 1, Week 3, and Week 6. Borg dyspnea scores during exercise, locus of symptom limitation, and safety measures were assessed. RESULTS: Aclidinium significantly improved ET on Day 1 (P = 0.0002), and improvements were sustained through Week 3 (P = 0.0007) and Week 6 (P = 0.0042) vs placebo. Compared with placebo, aclidinium improved trough FEV(1), IC, and IC/TLC at Weeks 3 and 6 (P < 0.05 for all). Exertional dyspnea scores at isotime were reduced on Day 1, Week 3, and Week 6 for aclidinium vs placebo (P < 0.05). Furthermore, the likelihood of stopping exercise due to breathing discomfort was lower in the aclidinium group at study end (P = 0.0208) compared with placebo. No differences in safety outcomes were reported between treatments. CONCLUSIONS: Aclidinium significantly increased exercise tolerance, improved airflow obstruction and lung hyperinflation, and was safe and well tolerated. REGISTRATION OF TRIAL: This trial was registered with (NCT00500318) under the name "A Study of Exercise Endurance and Lung Hyperinflation in Patients with Moderate to Severe COPD".
François Maltais; Bartolome Celli; Richard Casaburi; Janos Porszasz; Diana Jarreta; Beatriz Seoane; Cynthia Caracta
Related Documents :
2635256 - Effect of reduced training volume on cardiac function, vo2 max, and running performance.
1293416 - Effect of time of day on adaptive response to a 4-week aerobic exercise program.
20029096 - Training methods and intensity distribution of young world-class rowers.
14985996 - The effects of different inspiratory muscle training intensities on exercising heart ra...
10777756 - Photochemical oxygen consumption sensitized by a porphyrin phosphorescent probe in two ...
21136446 - The effect of exercise training on transverse tubules in normal, remodeled, and reverse...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-12-21
Journal Detail:
Title:  Respiratory medicine     Volume:  -     ISSN:  1532-3064     ISO Abbreviation:  -     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Centre de recherche, Institut Universitaire de cardiologie et de pneumologie de Québec, Université Laval, 2725 Chemin Sainte-Foy, Québec G1V 4G5, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Commonly used leukotriene B(4) receptor antagonists possess intrinsic activity as agonists in human ...
Next Document:  Severe obstructive sleep apnea increases cystatin C in clinically latent renal dysfunction.